Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting complement in therapy.

M Kirschfink1

  • 1Institute of Immunology, University of Heidelberg, Germany. k92@ix.urz.uni-heidelberg.de

Immunological Reviews
|June 21, 2001
PubMed
Summary
This summary is machine-generated.

Strategies targeting the complement system, a key player in inflammatory diseases, show promise. Research explores inhibitors and regulators to treat inflammatory conditions and enhance cancer therapy by overcoming resistance mechanisms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local complement activation in aqueous humor in patients with age-related macular degeneration.

Eye (London, England)·2017
Same author

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clinical and experimental immunology·2016
Same author

Dissection of CD20 regulation in lymphoma using RNAi.

Leukemia·2016
Same author

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Complement profile in neonates of different gestational ages.

Scandinavian journal of immunology·2014
Same author

Pulp progenitor cell recruitment is selectively guided by a C5a gradient.

Journal of dental research·2013

Area of Science:

  • Immunology and Pharmacology
  • Complement System Biology

Background:

  • Complement activation is increasingly implicated in the pathogenesis of numerous inflammatory diseases.
  • Existing research highlights the need for therapeutic strategies to modulate complement system activity.

Purpose of the Study:

  • To review current strategies for interfering with complement activation in inflammatory diseases.
  • To discuss the role of complement in xenograft rejection and potential therapeutic interventions.
  • To address the challenges posed by complement resistance mechanisms in antibody-based cancer therapy.

Main Methods:

  • Evaluation of endogenous soluble complement inhibitors (e.g., C1 inhibitor, recombinant soluble complement receptor 1, antibodies).
  • Assessment of strategies neutralizing complement anaphylatoxin C5a and interfering with complement receptor 3 (CR3)-mediated adhesion.

Related Experiment Videos

  • Analysis of membrane-bound complement regulators (CD55, CD46, CD59) in transgenic models for xenograft protection.
  • Investigation of pharmacologic interventions to overcome complement resistance in antitumor responses.

    • Main Results:

    • Successful testing of various complement inhibition strategies in animal models, leading to clinical trials.
    • Demonstrated efficacy of membrane-bound complement regulators in preventing xenograft hyperacute rejection.
    • Recognition of complement's limited role in antitumor responses due to resistance mechanisms.

    Conclusions:

    • Therapeutic targeting of the complement system offers significant potential for treating inflammatory diseases.
    • Complement regulators are crucial for successful xenotransplantation.
    • Developing strategies to overcome complement-mediated resistance is essential for improving antibody-based cancer immunotherapy.